Response to imatinib as a function of target kinase expression in recurrent glioblastoma

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Hassler, Marco Ronald ^a   Vedadinejad, Mariam ^a   Flechl, Birgit ^a   Haberler, Christine ^a   Preusser, Matthias ^a   Hainfellner, Johannes Andreas ^a   Wöhrer, Adelheid ^a   Dieckmann, Karin Ute ^a   Rössler, Karl ^b   Kast, Richard ^a   Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Dept of Neurology   (Austria)

Author keywords

Arg kinase; c Abl; c Fms; c kit; Cytokine; Glioblastoma; Inatinib; Markers; Platelet derived growth factor; Tyrosine kinase

Indexed keywords

EID: 84897747615     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-111     Document Type: Article

References (32)

1. Alterman RL, Stanley ER (1994) Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol 21(2-3):177-188.
2. Beaty BT, Sharma VP, Bravo-Cordero JJ, Simpson MA, Eddy RJ, Koleske AJ, Condeelis J (2013) β1 integrin regulates Arg to promote invadopodial maturation and matrix degradation. Mol Biol Cell, [Epub ahead of print] PubMed PMID:23552693.
3. Calabrese EJ (2012) Hormesis and the salk polio vaccine. Dose Response 10(1):91-95, doi: 10.2203/dose-response.11-032.
4. Coniglio SJ et al (2012) Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 18:519-527.
5. Cox LA Jr (2006) Universality of J-shaped and U-shaped dose-response relations as emergent properties of stochastic transition systems. Dose Response 3(3):353-368, doi: 10.2203/dose-response.0003.03.006.
6. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756-784, doi: 10.1101/gad.187922.112.
7. Franklin HR, Simonetti GP, Dubbelman AC, ten Bokkel Huinink WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB, Aaronson NK (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5(2):113-117.
8. George D (2003) Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 532:141-151.
9. Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha,-beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 76(2):105-109.
10. Hayes KE, Walk EL, Ammer AG, Kelley LC, Martin KH, Weed SA (2012) Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene, doi: 10.1038/onc.2012.513.
11. Hincal F, Gürbay A, Favier A (2003) Biphasic response of ciprofloxacin in human fibroblast cell cultures. Nonlinearity Biol Toxicol Med 1(4):481-492, doi: 0.1080/15401420390271083.
12. Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA (2010) Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 97:241-245, doi: 10.1007/s11060-009-0008-0.
13. Lennartsson J, Ronnstrand L (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92(4):1619-1649.
14. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, Jurgensmeier JM, Jones C (2012) Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 72(7):1614-1620, doi: 10.1158/0008-5472.CAN-11-4069.
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280.
16. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ, Gil-Henn H (2011) An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 71(5):1730-1741, doi: 10.1158/0008-5472.CAN-10-1432.
17. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi ER (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88(1):97-103, doi: 10.1007/s11060-008-9538-0.
18. Morris PG, Abrey LE (2010) Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas. Target Oncol 5(3):193-200.
19. Mouchemore KA, Pixley FJ (2012) CSF-1 signaling in macrophages: pleiotrophy through phosphotyrosine-based signaling pathways. Crit Rev Clin Lab Sci 49(2):49-61.
20. Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE (2013) Structure and dynamic regulation of Abl kinases. J Biol Chem 288(8):5443-5450, doi: 10.1074/jbc.R112.438382.
21. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26(28):4659-4665, doi: 10.1200/JCO.2008.16.9235.
22. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G (2009) Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 15(19):6258-6266, doi: 10.1158/1078-0432.CCR-08-1867. Epub 2009 Sep 29.
23. Soo GW, Law JH, Kan E, Tan SY, Lim WY, Chay G, Bukhari NI, Segarra I (2010) Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anticancer Drugs 21(7):695-703.
24. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466.
25. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109(8):3041-3046, doi: 10.1073/pnas.1114033109.
26. Tan SY, Kan E, Lim WY, Chay G, Law JH, Soo GW, Bukhari NI, Segarra I (2011) Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. J Pharm Pharmacol 63(7):918-925, doi: 10.1111/j.2042-7158.2011.01296.x.
27. Taphoorn MJ, Bottomley A (2005) Health-related quality of life and symptom research in glioblastoma multiforme patients. Expert Rev Pharmacoecon Outcomes Res 5(6):763-774.
28. Trotti A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-181.
29. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110, doi: 10.1016/j.ccr.2009.12.020.
30. Waller CF (2010) Imatinib mesylate. Recent results. Cancer Res 184:3-20, doi: 10.1007/978-3-642-01222-8.
31. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-4907.
32. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95(3):401-411, doi: 10.1007/s11060-009-9938-9.